Send to

Choose Destination
Biomed Hub. 2016 Dec 13;1(3):1-9. doi: 10.1159/000453253. eCollection 2016 Sep-Dec.

Personalized Cancer Care: Risk Prediction, Early Diagnosis, Progression, and Therapy.

Author information

Institute of Immunology and Experimental Oncology, Center for Biomedical Education and Research, University Witten/Herdecke, Witten, Germany.
Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Fritz-Bender Foundation, Munich, Germany.


At the annual prestigious International Symposium of the Fritz-Bender Foundation, Munich, 18-20 May, 2016, researchers, clinicians, and students discussed the state of the art and future perspectives of genomic medicine in cancer. Genomic medicine (also known as precision medicine/oncology) should help clinicians to provide a more precise diagnosis and therapy in oncology for individual patients. The meeting focused on next-generation sequencing methods, analytical computational analysis of big data, and data mining on the way to translational and evidence-based medicine. The meeting covered the social and ethical impact of genomic medicine as well as news and views on antibody targeting of intracellular proteins, on the architecture of intracellular proteins and their impact on carcinogenesis, and on the adaptation of tumor therapy in due consideration of tumor evolution. Subheadings like "Genetic Profiling of Patients and Risk Prediction," "Molecular Profiling of Tumors and Metastases," "Tumor-Host Microenvironment Interaction and Metabolism," and "Targeted Therapy" were subsumed under the main heading of "Personalized Cancer Care."


Early diagnosis; Progression; Risk prediction; Therapy

Supplemental Content

Full text links

Icon for PubMed Central Icon for Norwegian BIBSYS system
Loading ...
Support Center